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Abstract

Klinefelter Syndrome is a genetic disorder caused by the presence of supernumerary sex
chromosomes. An additional X chromosome(s) and hypogonadism are the two defining
features of Klinefelter syndrome (Groth, 2013). The excess of genes from the additional X
chromosome drives the pathogenesis of the disease and distinguishing features of the
affected individuals. Genotypic variants exist within the affected population, leading to
differences in phenotype and severity of symptoms (Bonomi, 2017). The increase in the
prevalence of prenatal testing has led to the earlier recognition of fetal chromosomal
abnormalities. Early detection of Klinefelter syndrome through noninvasive prenatal testing
is an extraordinary medical tool, giving the family much need information and allowing for
early intervention, ensuring the best outcome for the child (Groth, 2013). This case report
shows a patient that will greatly benefit from the early diagnosis of a genetic syndrome to
implement early and timely interventions upon delivery and then later on in the child’s
developing years.

Table 1. Klinefelter Syndrome’s Manifestations
- Modified table from Groth et al., 2013 publication on Clinical Features of KS

Feature
Infertility
Increased Gonadotrophin Hormones
Decreased Testicular Volume
Azoospermia
Learning Disability
Testosterone Deficiency
Decreased Distribution of Male Body Hair
Gynecomastia
Speech Delays
Increased Height
Case Report
A male infant was born at 37 weeks gestation. His mother was a 29-year-old, gravida 4 para 3
Elevated BMI
woman. During her pregnancy she was curious as to the gender of the fetus and requested a
Metabolic Syndrome
non-invasive prenatal test (NIPT) rather than fetal ultrasound. The NIPT returned with a
Decreased Bone Density
karyotype of XXY. The male infant was born vaginally with a birth weight of 2670 grams.
Type II Diabetes Mellitus
Apgar scores were 8 and 9 at one and five minutes respectively. He was admitted to the
Cryptorchidism
newborn intensive care unit secondary to respiratory distress. He had no obvious
Decreased Penile Size
dysmorphic features. He had normal appearing male genitalia with testes descended
bilaterally. Fluorescent in situ hybridization and blood chromosomes confirmed an XXY
Psychiatric Conditions
karyotype. He was discharged from the newborn intensive care unit with follow up by
Congenital Malf. (i.e. Cleft lip, Inguinal
genetic counselors and close monitoring for developmental delays.
Hernia)
Cardiovascular Abnormalities
Genetics

Supernumerary X chromosomal aneuploidy leads to the majority (80%) of Klinefelter
individuals possessing the karyotypic pattern 47XXY (Bonomi, 2017). This arises due to
nondisjunction occurring in gametogenesis. Nondisjunction arises equally from paternal and
maternal origins. The remaining minority of genotypes includes, but is not limited to,
47,XXY/46,XY mosaicism, 48,XXXY/47,XXY, and 48,XXXY. arises due to the non-disjunction
event of the X chromosome occurring in the early mitotic stages of the developing 46,XY
zygote or through a X chromosome being lost due to anaphase lag in the mitotic
development of a 47,XXY zygote (Bonomi, 2017).
Nondisjunction occurs
during meiosis of the
respective gametes:
• Meiosis I or II of
maternal Oocyte
• Meiosis I of paternal
Spermatocyte
Genotypic factors driving
phenotype and variance:
• Gene dosage by
additional X
• CAG repeat
polymorphisms
• Pseudo autosomal
regions (PARs)
expressed
Gene’s copy number
Figure 1, Non-disjuntional of Klinefelter producing gametogenesis. (Kanakis, •
variants (CNVs)
2018)

Tentative Frequency
> 95%
> 95%
> 95%
> 95%
> 75%
60-85%
30-80%
40-75%
40%
30%
~50%
46%
5-40%
10-40%
37%
10-25%
25%
18%
0-55%

Table 1, KS Manifestations and general frequency of presentation in confirmed cases (Groth, 2013).

Clinical Consideration

Klinefelter Syndrome can present with any number of symptoms as indicated by table 1. It’s
understood that these symptoms are attributed to several factors.
• Number of genetic abnormalities (# of X, CAG repeats, PARs, & CNVs)
• Androgen dependent, Supernumerary X, or combined factors
• Age of presenting individual (symptoms worsen with age)
These features can be grouped by age of onset, androgen-dependence, supernumerary Xdependence, or combined etiology (Bonomi, 2017).
The neonate in question presents with no distinct, characteristic signs of Klinefelter Syndrome,
which is common in many individuals. Due to the underwhelming and subtle nature of many
Klinefelter phenotypes, a majority of patients go undiagnosed. Only two findings, other then the
NIPT results, weakly suggest a possible abnormality.
• Respiratory distress seen in 9.2% of KS births as opposed to 1.2% in normal neonates (DottersKatz, 2016).
• Lower than normal birth weights for gestational age have been reported in KS neonates
(Dotters-Katz, 2016), but as of this time, low birth weight alone does not give reason to
suspect Klinefelter Syndrome.
The underwhelming clinical presentation of the neonate shows that if NIPT wasn’t conducted,
neither our patient nor his family would have known he was 47,XXY, until much later in life. Timely
hormonal intervention is possible for our patient because of NIPT. This demonstrates a need of a
standard KS screen.

Non-Invasive Prenatal Testing

Non-invasive prenatal testing (NIPT), also known as cell-free DNA testing, is a prenatal
screening tool used in the assessment of fetal chromosomal abnormalities. Cell-free DNA
can be found in all individuals as a result of the natural turnover of cells. Small DNA
fragments from this cellular turnover is found briefly in circulating blood plasma prior to
being cleared. In pregnant mothers, a fraction of the small DNA fragments found in
circulating plasma is from the outer trophoblastic cell layer of the placenta. These
trophoblasts DNA fragments usually match the genotype of the developing fetus. A blood
sample is drawn from the mother, then plasma concentrations of cell free DNA are divided
into maternal and fetal fractions. This fetal fraction is compared to normal standards for the
corresponding gestational age of the fetus. Individual chromosomes appear at known
standard ratios within the fetal fraction. Ratios that deviate from the norm indicate an
abnormality in that particular chromosome (Harraway, 2017). WHO’s criteria for use of the
test in listed in table 2.

World Health Organization’s Criteria for NIPT
The condition should be an important health problem
The natural history of the condition should be adequately
Facilities for diagnosis and treatment should be available
The overall benefit of screening should outweigh the harm
There should be scientific evidence regarding screening program
effectiveness
The screening program should respond to a recognized need
The objectives of screening should be defined at the outset
Table 2, WHO’s criteria for non-invasive prenatal testing (Suciu, 2019)

Discussion

Klinefelter’s Syndrome carries with it a significant number of manageable symptoms and
considerable comorbidities. With a larger number of men, up to 70-75%, going undiagnosed
throughout their lifetime (Bojesen, 2003). Screening is needed to help in the diagnoses of
the vast majority of these patients. With the technology of NIPT advancing and improving in
its ability to detect a variety of other conditions outside of the traditional autosomal
aneuploidy, it should be considered a technique for screening for clinically silent conditions,
such as mild Klinefelter syndrome phonotypes. When a majority of patients are going
undiagnosed and untreated the benefit of adding sex chromosomal aneuploidy to the test is
two-fold. One if it allows for use to detect patients that would otherwise go undiagnosed
until later in life, resulting in late introduction of testosterone replacement therapies,
missing the critical stage of puberty. Second it allows us to improve our understanding of
Klinefelter patients’ development during early childhood and the use of NIPT in prenatal
diagnostics overall.
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